Ketamine, benzoate, and sarcosine for treating depression

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Depression is a debilitating mental health condition with limited treatment options.
• Current treatments for depression do not address all patients effectively.
• Emerging research suggests novel therapeutic targets for depression.

Purpose of the Study:

• To review and compare the therapeutic mechanisms of sarcosine, benzoate, and ketamine (including esketamine and arketamine) for depression.
• To explore the roles of N-methyl-d-aspartate glutamate receptors (NMDARs) and neuroinflammation in depression.
• To evaluate the potential of these compounds as novel antidepressants.

Main Methods:

• Literature review of in vitro and in vivo studies.
• Analysis of studies on NMDAR modulation by sarcosine, benzoate, and ketamine.
• Investigation of the anti-inflammatory effects of these compounds, particularly on microglial activity.

Main Results:

• Sarcosine, benzoate, and ketamine demonstrate therapeutic effects in depression models and human trials.
• These compounds modulate NMDARs through various mechanisms (antagonism or co-agonism).
• Sarcosine, benzoate, and ketamine exhibit anti-inflammatory properties by inhibiting microglial activity.

Conclusions:

• Sarcosine, benzoate, and ketamine show promise as effective treatments for depression.
• Their dual action as NMDAR modulators and anti-inflammatory agents contributes to their efficacy.
• Further research into these compounds could lead to new therapeutic strategies for depression.